Biomarker for Gleason Score 7 Prostate Cancer Can Predict Aggressiveness
the Cancer Therapy Advisor take:
According to a new study published in the journal Clinical Cancer Research, researchers at the University of Texas MD Anderson Cancer Center in Houston, Texas, have identified a genetic variant near the KLK3 gene that can predict which patients with prostate cancer and a Gleason score of 7 will have a more aggressive type of the disease.
Prostate cancers associated with a Gleason score of 7 are an intermediate grade of cancer and account for about 30% to 40% of all prostate cancers. This biomarker could allow clinicians to determine whether patients will have a slow-growing or aggressive form of prostate cancer, allowing for better decision regarding treatment options.
For the study, the researchers analyzed the genetic makeup of 72 single nucleotide polymorphisms in 1,827 patients with prostate cancer. They then identified associations between the polymophisms and prostate cancer aggression. They found one polymorphism on the KLK3 gene on chromosome 19 that can predict whether or not a patient with prostate cancer and a Gleason score of 7 will have an aggressive form of the disease.
It can be sometimes difficult to determine the best treatment option for a patient with a Gleason score of 7 because the patient's cancer could be slow-growing or aggressive.
KLK3 gene predicts more aggressive type of the disease.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Plastics and Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer